# NCT02414139 (NCT02414139)

> Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02414139
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Capmatinib
- Enrollment: 373
- Primary outcome: Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) Assessment

## Commentary we found

- YouTube: 5
- Podcasts: 3
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02414139

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02414139", "email": "<work email>"}; the inbox owner confirms by the emailed link.